electroCore Announces Key Addition to Their Leadership Team
In an exciting development for electroCore, Inc. (NASDAQ: ECOR), the company has successfully appointed Andy Brown as their new Vice President, Corporate Controller. This announcement signals a pivotal moment for the company as it thrives in the realm of bioelectronic medicine and wellness.
Details of the Inducement Stock Grants
As part of his transition into this significant role, Mr. Brown has been awarded 10,000 restricted stock units (RSUs). This grant comes under NASDAQ Listing Rule 5635(c)(4), emphasizing the importance of these stock units to Mr. Brown's employment commencement. This strategic move reflects the company’s commitment to attracting top talent by offering competitive incentives that align with its growth objectives.
Understanding Restricted Stock Units
The structure of these RSUs is designed to motivate and retain talent by providing a clear incentive tied to the company’s performance. Specifically, one-third of these RSUs will vest on each of the first three anniversaries of the grant date, contingent on Mr. Brown's ongoing employment with electroCore. Upon vesting, the units will convert into shares of the company’s common stock, creating a direct link between the company's success and Mr. Brown’s personal achievements.
About electroCore and Its Innovative Solutions
Founded with a mission to enhance health and quality of life through cutting-edge technology, electroCore, Inc. is at the forefront of bioelectronic medicine. Their offerings include the gammaCore non-invasive vagus nerve stimulation (nVNS) device and the Quell neurostimulator, both designed to address chronic pain syndromes using innovative neuromodulation technology.
Beyond Pain Management
In addition to its flagship products, electroCore also markets handheld devices such as Truvaga and TAC-STIM, aimed at promoting overall wellness and improving human performance. This diverse product range highlights the company’s dedication to leveraging bioelectronic technologies, aiming to transform the health sector by providing effective and non-invasive treatment options.
The Future of electroCore
As electroCore continues to expand, the appointment of executives like Mr. Brown is crucial. Their ability to attract qualified individuals indicates strong corporate foresight and the ambition to remain competitive within the growing bioelectronic sector. By enhancing their leadership team, electroCore is better positioned for strategic growth and innovation in the years to come.
For those eager to follow the developments at electroCore, the company remains committed to transparent communication with investors and stakeholders, as evidenced by their robust investor relations framework.
Contact Information:
For inquiries, please reach out to ECOR Investor Relations at (973) 302-9253 or via email at investors@electrocore.com.
Frequently Asked Questions
What is electroCore, Inc.?
electroCore, Inc. is a bioelectronic medicine company focused on developing innovative technology to improve health and wellness.
Who is the newly appointed VP at electroCore?
Andy Brown has been appointed as the new VP, Corporate Controller at electroCore.
What are restricted stock units?
Restricted stock units (RSUs) are a form of equity compensation offered by companies to employees as part of their remuneration package.
How many RSUs has Andy Brown been granted?
Andy Brown has been granted 10,000 RSUs as part of his employment agreement with electroCore.
What products does electroCore offer?
electroCore offers a range of products including gammaCore, Quell, Truvaga and TAC-STIM focused on wellness and pain management.
